Spotlight Medical Secures IVDR CE Marking for myStage Dx, Its AI-Enabled Prognostic Test for ER+/HER2 – Early Breast Cancer
Careers
Ready to shape the future of cancer treatment? Join us!
We turn clinical evidence into prognostic assays that help clinicians make more precise risk assessments for cancer patients.
Context
Cancer affects
0
1
2
3
4
5
6
7
8
9
0
0
1
2
3
4
5
6
7
8
9
0
of the global population
and this number is rapidly increasing.
Shot of a senior man having a consultation with his male doctor.
Portrait of mature woman smiling while talking to female doctor during consultation in clinic, copy space
Serious GP doctor showing tablet screen to old 70s female patient, explaining electronic prescription, medical screening, examination result, giving consultation. Woman visiting practitioner
Caring doctor listens to patient
Clinical risk is not always biological risk.
Patients classified in the same clinical risk group may have different outcomes after standard therapy.
Clinicians need better tools to understand each patient’s true risk.
Spotlight builds a new category of assays to make that risk clearer.
Revealing more precise prognosis
Serious GP doctor showing tablet screen to old 70s female patient, explaining electronic prescription, medical screening, examination result, giving consultation. Woman visiting practitioner
Introducing myStage Dx™
The first prognostic test for node-positive, ER-positive, HER2-negative early-stage breast cancer, designed to help clinicians identify patients who may have a favorable outcome despite high-risk clinical features. The test is CE-IVDR marked and supported by peer-reviewed clinical evidence published in the Journal of Clinical Oncology.
Our Vision
We believe that every patient should receive the most effective cancer care, tailored to their individual needs.
We leverage decades of patient data to provide precise insights
Our technology analyses routine H&E slides, and uses AI to combine standard baseline characteristics with slide-derived features on tumor and microenvironment, and returns actionable relapse scores.
Our latest news
23 Jun 2026
25 Aug 2025
12 Jul 2024
No results